Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s540327 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Yifei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi, 332001, People's Republic …. Hauptthemen laut MEDLINE: Palmitic Acids, Ethanolamines, Pain, Analgesics. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Palmitoylethanolamide (PEA) has attracted increasing attention from researchers as an endogenous lipid mediator. It exhibits a unique mechanism of action in alleviating pain, controlling inflammation, and providing neuroprotection. It primarily regulates downstream signaling pathways by activating peroxisome proliferator-activated receptor alpha (PPAR-α) to inhibit the activity of nuclear factor kappa B (NF-κB), thereby reducing the production of pro-inflammatory cytokines. Additionally, PEA interacts synergistically with the endogenous cannabinoid system to modulate neurotransmission by enhancing the function of endogenous cannabinoids. The anti-inflammatory effects of PEA are also reflected in the regulation of glial cells and mast cells, effectively reducing local and central inflammation, thus protecting neuronal cells and promoting their regeneration. Clinical studies have shown that the application of PEA in various types of pain demonstrates good safety and tolerability, particularly suited for use in combination with traditional analgesics to enhance efficacy, reduce dependence, and minimize side effects. Despite existing research proving the effectiveness of PEA, challenges remain in its clinical promotion, including dosage form diversity, overall insufficient evidence, and patient individual differences. Therefore, future efforts should focus on strengthening multi-center large sample randomized controlled trials, coupled with biomarker investigations for personalized treatment research, to facilitate the widespread application of PEA in clinical pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People's Hospital, Jiujiang, Jiangxi, 332001, People's Republic of China.
- Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, People's Republic of China.
ORCID-Profile: Yuanming Pan
Zitieren
APA
Wang, Y., Duan, X., Li, Z., Pan, Y., & Deng, J. (2025). Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s540327
Vancouver
Wang Y, Duan X, Li Z, Pan Y, Deng J. Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s540327
BibTeX
@article{Wang2025,
author = {Wang, Yifei and Duan, Xunhuang and Li, Zhiqi and Pan, Yuanming and Deng, Jianhua},
title = {Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s540327}
}
EUVIMED